Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT).

Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Abstract Text:

From the first decade of this century arsenicals have been the most universal and most effective drugs for all cases of sleeping sickness. Melarsoprol, introduced in the 1940s, remains the most universal of these compounds. However, resistance of trypanosomes and toxicity that may be fatal for the patient are two major shortcomings. Pentamidine, suramin and Berenil((R)) are active only in the first stage of the disease, when the parasites are confined to blood and lymph. Nifurtimox taken orally for 1 to 2 months and alpha-difluoro-methylornithine (alpha-DFMO) with an administration scheme spread over 5 weeks including 14 days of intravenous injections. provide interesting alternatives for all cases, since they reach the central nervous system. However, DFMO is known to be less active against. T. rhodesiense. Imidazoles, new arsenical derivatives and antimitotics have been successfully tested in experimental models. Combinations of drugs with additive or pontentiating effects mainly based on inhibition of decarboxylase enzymes or exposure to axidative stress appear promising.

Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of antimicrobial agents

VOLUME: 4

Page Numbers: 227-38

Journal Abbreviation: Int. J. Antimicrob. Agents

ISSN: 0924-8579

DAY: 9

MONTH: Aug

YEAR: 1994

Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9111860

Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT).

AFFILIATION: Institute of Tropical Medicine, 155 Nationalestraat B-2000 Antwerp, Belgium.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Antimicrob Agents

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug used in the treatment of sleeping sickness human African trypanosomiasis: HAT Related Publications

• A highly efficient in vitro cloning procedure for asexual erythrocytic forms of the human malaria parasite Plasmodium falciparum.
• An etiologic study of hemoglobinuria and blackwater fever in the Kivu Mountains, Zaire.
• Bioproduction of p-hydroxybenzoate from renewable feedstock by solvent-tolerant Pseudomonas putida S12.
• Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT).
• Indirect immunofluorescence using differentiating antigens in detection of imported malaria.
• Line immunoassay: a new serologic test for malaria.
• Population dynamics of anophelines in a malathion treated village in the intermediate zone of Sri Lanka.
• Studies on the sporogony of rodent malaria parasites.
• Transcriptome Analysis of a Phenol-Producing Pseudomonas putida S12 Construct: Genetic and Physiological Basis for Improved Production.
• Use of freeze-dried trypanosomes in the indirect fluorescent antibody test for the serodiagnosis of sleeping sickness.
• [Analysis of the frequency distribution of cellular volumes of Trypanosoma brucei gambiense developing in the blood and cerebral interstitium of mice]
• [Bacteriostatic activity of 3,5-dichloro-4'-fluorothiocarbanilide.]
• [Bovine schistosomiasis in Ruanda-Urundi (Belgian Congo).]
• [Conclusions of the international conference on African trypanosomiasis in humans]
• [Criteria and circumstances of viability of gametocytes of Plasmodium berghei]
• [Effect of maintaining a strain of Plasmodium berghei Anka on gametogenesis]
• [Malaria index according to age and seasons in the health region of Katana, in mountainous Kivu, Zaire]
• [Methods and expenses for protection against mosquitoes in households in Kinshasa, Zaire]
• [Methods for a more accurate control of the development of experimental trypanosomiasis caused by trypanosoma brucei gambiense in mice]
• [Not Available.]
• [Not Available.]
• [Observations on the diamidine sensitivity of strains of Trypanosoma gambiense recently isolated in the Republic of Zaire]
• [Onchocerciasis on the left bank of the Upper Inzia, in Zaire: ophthalmological and parasitological aspects]
• [Presence of small native focus of bilharziasis with Schistosoma mansoni at Kinshasa (Republic of Zaire)]
• [Study of the cycle of Plasmodium berghei yoelii in view of the massive production of viable sporozoites and exo-erythrocytary forms]
• [Survey of the epidemiological status of malaria in Kinshasa (Republic of Zaire) in 1980]
• [The importance of drug associations in the treatment of diarrhea.]
• [The in-vitro action of chloroquine on the infectivity of gametocytes of Plasmodium berghei Anka]
• [Too sensitive a diagnosis or too toxic a treatment?]
• [Value of the quantitative buffy coat test (QBC) as a method in the microscopic diagnosis of malaria]